Aryx Therapeutics I Probability of Future Pink Sheet Price Finishing Under 4.25E-4

ARYXDelisted Stock  USD 0.0005  0.00  0.00%   
Aryx Therapeutics' future price is the expected price of Aryx Therapeutics instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Aryx Therapeutics I performance during a given time horizon utilizing its historical volatility. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
  
Please specify Aryx Therapeutics' target price for which you would like Aryx Therapeutics odds to be computed.

Aryx Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Aryx Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Aryx Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Aryx Therapeutics is not yet fully synchronised with the market data
Aryx Therapeutics has some characteristics of a very speculative penny stock
Aryx Therapeutics has a very high chance of going through financial distress in the upcoming years
The company has a current ratio of 0.46, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Aryx Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Aryx Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Aryx Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Aryx to invest in growth at high rates of return. When we think about Aryx Therapeutics' use of debt, we should always consider it together with cash and equity.
Net Loss for the year was (33.17 M) with profit before overhead, payroll, taxes, and interest of 0.
Aryx Therapeutics I currently holds about 2.95 M in cash with (34.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09, which can makes it an attractive takeover target, given it will continue generating positive cash flow.

Aryx Therapeutics Technical Analysis

Aryx Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Aryx Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Aryx Therapeutics I. In general, you should focus on analyzing Aryx Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.

Aryx Therapeutics Predictive Forecast Models

Aryx Therapeutics' time-series forecasting models is one of many Aryx Therapeutics' pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Aryx Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.

Things to note about Aryx Therapeutics

Checking the ongoing alerts about Aryx Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Aryx Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Aryx Therapeutics is not yet fully synchronised with the market data
Aryx Therapeutics has some characteristics of a very speculative penny stock
Aryx Therapeutics has a very high chance of going through financial distress in the upcoming years
The company has a current ratio of 0.46, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Aryx Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Aryx Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Aryx Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Aryx to invest in growth at high rates of return. When we think about Aryx Therapeutics' use of debt, we should always consider it together with cash and equity.
Net Loss for the year was (33.17 M) with profit before overhead, payroll, taxes, and interest of 0.
Aryx Therapeutics I currently holds about 2.95 M in cash with (34.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Other Consideration for investing in Aryx Pink Sheet

If you are still planning to invest in Aryx Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aryx Therapeutics' history and understand the potential risks before investing.
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Fundamental Analysis
View fundamental data based on most recent published financial statements
Transaction History
View history of all your transactions and understand their impact on performance
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets